

FDA Good Clinical Practice 2022 Reference Guide

(April 1, 2023 - March 31, 2024)

- **Code of Federal Regulations (CFR)**

- **Title 21: Food & Drugs**

- Revised as of April 1, 2023

- Part 11: Electronic Records; Electronic Signatures
 - Part 50: Protection of Human Subjects
 - Part 54: Financial Disclosure by Clinical Investigators
 - Part 56: Institutional Review Boards
 - Part 312: Investigational New Drug Application
 - Sections 314.80, 314.81: Post-Marketing Reporting
 - Section 314.126: Adequate and Well-Controlled Studies

- **Index to 21 CFR parts 11, 50, 54, 56, 312, 314**

- **FDA Information Sheet Guidances**

- Includes:

- Frequently Asked Questions on Clinical Research
 - A Guide to Informed Consent
 - Recruiting Study Subjects
 - Frequently Asked Question about FDA Form 1572
 - Pre-Study Screening Tests
 - Foreign Clinical Studies for US Submission
 - FDA Inspections of IRBs and Investigators

- **ICH Guidelines (Step 5, U.S.)**

- E6(R2): Integrated Addendum to E6(R1): Guideline For Good Clinical Practice (Step 5 US + ICH Step 4 Addenda)
 - E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
 - E8: General Considerations for Clinical Trials

- **FDA Guidance Documents**

- Adverse Event Reporting to IRBs
 - Safety Reporting Requirements for INDs and BA/BE Studies
 - A Risk-Based Approach to Monitoring
 - FDA Inspections: Compliance Program Guidance #7348.810

- **2023 International Websites on Drug Development**

- **European Directives on GCP**

- 2001/20/EC and 2005/28/EC